TURNOVER (x1000 SEK)
NET PROFIT (x1000 SEK)
EMPLOYEES
Swedish Orphan Biovitrum AB (publ)
Closing information (x1000 SEK)
| Closing information | 2023/12 (consolidated) | 2022/12 (consolidated) | 2021/12 (consolidated) |
| Turnover |
22,123,000
|
18,790,000
|
15,529,000 |
| Financial expenses |
1,162,000
|
497,000
|
454,000 |
| Earnings before taxes |
2,954,000
|
3,321,000
|
3,295,000 |
| EBITDA |
7,234,000
|
6,087,000
|
5,733,000 |
| Total assets |
74,027,000
|
52,496,000
|
48,661,000 |
| Current assets |
12,671,000
|
11,211,000
|
8,778,000 |
| Current liabilities |
19,095,000
|
14,857,000
|
8,761,000 |
| Equity capital |
33,867,000
|
26,525,000
|
23,203,000 |
| - share capital |
194,000
|
170,000
|
169,000 |
| Employees (average) |
1,772
|
1,556
|
1,559 |
Financial ratios
| Fiscal year | 2023/12 (consolidated) | 2022/12 (consolidated) | 2021/12 (consolidated) |
| Solvency |
45.7%
|
50.5%
|
47.7% |
| Turnover per employee |
12,485
|
12,076
|
9,961 |
| Profit as a percentage of turnover |
13.4%
|
17.7%
|
21.2% |
| Return on assets (ROA) |
5.6%
|
7.3%
|
7.7% |
| Current ratio |
66.4%
|
75.5%
|
100.2% |
| Return on equity (ROE) |
8.7%
|
12.5%
|
14.2% |
| Change turnover |
3,333,000
|
3,261,000
|
268,000 |
| Change turnover % |
18%
|
21%
|
2% |
| Chg. No. of employees |
216
|
-3
|
50 |
| Chg. No. of employees % |
14%
|
0%
|
3% |
Total value of public sale
| Fiscal year | 2023/12 (consolidated) | 2022/12 (consolidated) | 2021/12 (consolidated) |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.